Zoetis (ZTS)
(Delayed Data from NYSE)
$159.70 USD
+1.28 (0.81%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $159.76 +0.06 (0.04%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$159.70 USD
+1.28 (0.81%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $159.76 +0.06 (0.04%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth F Momentum D VGM
Zacks News
Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).
Why Is Zoetis (ZTS) Up 3.1% Since the Last Earnings Report?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Research Reports for March 9, 2017
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including IBM (IBM), Celgene (CELG), and Shell (RDS.A).
Zoetis (ZTS) Beats Q4 Earnings Estimates, Lowers Outlook
by Zacks Equity Research
Zoetis Inc. (ZTS) topped earnings estimates in the fourth-quarter of 2016 while revenues came in line. The company also narrowed its outlook for 2017 to account for currency impact.
Zoetis (ZTS) Tops on Earnings in Q4, Updates View
by Ekta Bagri
Zoetis has surpassed earnings estimates in Q4 but revenues came in line. The company also updated its outlook for 2017.
5 Easy Money Momentum Stocks To Buy Now
by David Bartosiak
These 5 stocks are breaking through to new 52-week highs on huge momentum
Top Research Reports for December 29, 2016
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), Danaher (DHR) and Colgate-Palmolive (CL).
Top Research Reports for Broadcom, PNC Financial & ConocoPhillips
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Broadcom (AVGO), PNC Financial Services (PNC) and ConocoPhillips (COP).
5 Healthcare Stocks Poised to Trump Q3 Earnings
by Zacks Equity Research
Medical is one of the many sectors that is witnessing earnings and revenue growth this quarter.
Top Research Reports for August 19, 2016
by Sheraz Mian
Today's must-read reports are for Verizon (VZ), Comcast (CMCSA) and Teva (TEVA).
Bear of the Day: Valeant Pharma (VRX)
by Brian Hamilton
The company is facing legal, accounting, and negative pricing issues.